Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Meibergdreef 9, Amsterdam, Netherlands.
Expert Opin Ther Targets. 2010 Mar;14(3):253-64. doi: 10.1517/14728220903551304.
Autoimmune inflammatory diseases occur commonly in developed countries. The treatment of these diseases is usually non-curative and is aimed at suppressing inflammatory end-organ damage. Macrophage migration inhibitory factor (MIF) is a multipotent cytokine that has been implicated in the pathogenesis of numerous autoimmune inflammatory disorders. The selective targeting of MIF with either anti-MIF antibody or specific MIF antagonists may offer new therapeutic avenues for these diseases.
Our aim is to discuss MIF-directed therapies as a novel therapeutic approach. The review covers literature from the past 10 years.
MIF inhibition has been shown to be efficacious in many experimental and pre-clinical studies of autoimmune inflammatory diseases. The close regulatory relationship between MIF and glucocorticoids makes therapeutic antagonism of MIF a potential steroid-sparing therapy in patients with refractory autoimmune diseases.
We expect that MIF antagonism by either small-molecule- or antibody-based approaches will find wide application in the treatment of autoimmune inflammatory diseases. Such therapy also may be informed by the MIF genotype of affected patients.
自身免疫性炎症性疾病在发达国家很常见。这些疾病的治疗通常是不可治愈的，目的是抑制炎症终末器官的损伤。巨噬细胞移动抑制因子（MIF）是一种多功能细胞因子，与许多自身免疫性炎症性疾病的发病机制有关。用抗 MIF 抗体或特异性 MIF 拮抗剂选择性靶向 MIF，可能为这些疾病提供新的治疗途径。
这篇综述涵盖了过去 10 年的文献。
MIF 抑制已被证明在许多自身免疫性炎症性疾病的实验和临床前研究中是有效的。MIF 和糖皮质激素之间的密切调节关系使得 MIF 的治疗性拮抗作用成为治疗难治性自身免疫性疾病的潜在类固醇节约疗法。
我们预计，基于小分子或抗体的 MIF 拮抗作用将在自身免疫性炎症性疾病的治疗中得到广泛应用。这种治疗也可能受到受影响患者的 MIF 基因型的影响。
